The trial will evaluate the safety and tolerability of Tinlarebant and its potential to reduce atrophic lesion growth rate in patients diagnosed with GA in dry AMD.Read More
Belite Bio completes enrollment in global phase 3 PHOENIX trial for geographic atrophy
